Overview
Vaccine-induced fibrosarcoma is a rare adverse event following immunization (AEFI) characterized by the development of fibrosarcomas potentially linked to vaccine components, particularly aluminum adjuvants. The condition is not extensively documented in the provided abstracts, but concerns about rare adverse events following immunization are highlighted across multiple studies focusing on vaccine safety surveillance 12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576.Diagnosis
Management
Special Populations
References
Showing 100 most recent of 148 indexed papers.
1 Crépeaux G, Hammond JR, Handley JB, Hooker B, Jablonowski K, Luján L et al.. Aluminium adjuvants and childhood health: a call for science. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2026. link 2 Zauche LH, Miller ER, Kim SS, Jazwa A, Shay DK. Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems. Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2026. link 3 Stergachis A, Sevene E, Alam MGS, Chandler RE, Precioso A, Mudigonda S et al.. Systematic Review of Active Safety Surveillance of Vaccines and Medicines in Low- and Middle-Income Countries. Drug safety 2026. link 4 Katsuta T, Sato S, Kawazoe Y, Fukuda H. Active vaccine safety monitoring system using health insurance claims data in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Vaccine 2026. link 5 Yoon JG, Nham E, Choi YJ, Choi MJ, Choi WS, Yoon YK et al.. Establishing an Active Vaccine Safety Surveillance System Using Large Scale Databases in Korea: Lessons and Scalable Insights for Global Application. Journal of Korean medical science 2026. link 6 Chandra LA, Nugroho DB, Thobari JA, Dimaguila GL, Buttery J. Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review. Vaccine 2026. link 7 Cohen J. Florida plan to nix vaccine mandates raises alarm. Science (New York, N.Y.) 2025. link 8 Khademi S, Black J, Palmer C, Javed M, Clothier H, Buttery J et al.. Enhancing Vaccine Safety Surveillance: Extracting Vaccine Mentions from Emergency Department Triage Notes Using Fine-Tuned Large Language Models. Studies in health technology and informatics 2025. link 9 Zhu J, Vazquez-Benitez G, DeSilva MB, Kuckler L, Trower N, Muscoplat MH et al.. Increased Identification of Vaccines for Vaccine Safety Surveillance Through Linkage With the Minnesota Immunization Information Connection as of December 31, 2023. Public health reports (Washington, D.C. : 1974) 2025. link 10 Shaum A, Blau E, Longley A, Huang WT, Gidudu J. Strengthening New Vaccine Introduction in Low- and Middle-Income Countries: Establishing Hospital-Based Sentinel Surveillance for Vaccine Safety Monitoring. The American journal of tropical medicine and hygiene 2025. link 11 de Oliveira PMN, Hartmann K, Bhamare C, Lucchesi MBB. Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries. Vaccine 2025. link 12 Gilano G, Sako S, Molla B, Dekker A, Fijten R. The effect of mHealth on childhood vaccination in Africa: A systematic review and meta-analysis. PloS one 2024. link 13 Eichman D, Bichianu D. From Cotton Mather to Dr Fauci: Historical Markers of Vaccine Hesitancy. NeoReviews 2024. link 14 Eichman D, Bichianu D. From Cotton Mather to Dr Fauci: Historical Markers of Vaccine Hesitancy. NeoReviews 2024. link 15 Pascual-Ferrá P, Alperstein N, Burleson J, Jamison AM, Bhaktaram A, Rath S et al.. Assessing Message Deployment During Public Health Emergencies Through Social Media: Empirical Test of Optimizing Content for Effective Dissemination. Journal of medical Internet research 2024. link 16 França AP, Barata RB, Guibu IA, Moraes JC, Silva AID, Ramos AN et al.. Full vaccination coverage with valid doses among the 2017 and 2018 live birth cohort in the Southeast region of Brazil. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil 2024. link 17 Tan X, Wang W, Zeng D, Liu GF, Diao G, Jafari N et al.. Safety signal detection with control of latent factors. Statistics in medicine 2024. link 18 Morgan HJ, Clothier HJ, Witowski P, Boyd JH, Kattan GS, Dimaguila GL et al.. Establishing the Vaccine Safety Health Link: A large, linked data resource for the investigation of vaccine safety concerns. Australian and New Zealand journal of public health 2024. link 19 Clothier HJ, Shetty AN, Mesfin Y, Mackie M, Pearce C, Buttery JP. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety. Vaccine 2024. link 20 Poland GA, Black S. Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines. Vaccine 2024. link 21 Salmon DA, Chen RT, Black S, Sharfstein J. Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program. Expert opinion on drug safety 2024. link 22 Lee S, Lee K, Park J, Jeong YD, Jo H, Kim S et al.. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database. Journal of medical virology 2024. link 23 Male V. Vaccine hesitancy: current and future challenges. Immunology and cell biology 2023. link 24 Fantasia HC. Addressing Vaccine Hesitancy During the Perinatal Period. Nursing for women's health 2023. link 25 Opp MR. Sleep: Not getting enough diminishes vaccine responses. Current biology : CB 2023. link 26 Campos-Outcalt D. 5 non-COVID vaccine recommendations from ACIP. The Journal of family practice 2023. link 27 Christou-Ergos M, Wiley KE, Leask J. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others. Vaccine 2023. link 28 Shen R, Moll K, Lu Y, Tian L. A seasonality-adjusted sequential test for vaccine safety surveillance. Biometrics 2023. link 29 Zeleke ED, Yimer G, Lisanework L, Chen RT, Huang WT, Wang SH et al.. System and facility readiness assessment for conducting active surveillance of adverse events following immunization in Addis Ababa, Ethiopia. International health 2023. link 30 Suzuki S, Imai S, Mitsuboshi S, Kizaki H, Hashiguchi M, Hori S. Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System. Journal of clinical pharmacology 2023. link 31 Nyambayo PPM, Gold MS, Mehta UC, Clarke S, Manyevere R, Chirinda L et al.. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial. Vaccine 2023. link 32 Kelso JM. The adverse reactions to vaccines practice parameter 10 years on-what have we learned?. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2022. link 33 Talbird SE, Carrico J, La EM, Carias C, Marshall GS, Roberts CS et al.. Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States. Pediatrics 2022. link 34 Couzin-Frankel J. Global project gears up to study vaccine safety. Science (New York, N.Y.) 2022. link 35 Buttery JP, Clothier H. Information systems for vaccine safety surveillance. Human vaccines & immunotherapeutics 2022. link 36 Benbow DI. The Dizziness of Freedom: Understanding and Responding to Vaccine Anxieties. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 2021. link 37 Gaillat J. Where are the keys to improve vaccine uptake in adults and elders in European countries?. Aging clinical and experimental research 2021. link 38 Li S, Zhao L. Vaccine adverse event enrichment tests. Statistics in medicine 2021. link 39 Miyazaki M, Sakai T, Obara T, Mano N. The impact of regulation changes in the spontaneous reporting system for vaccines on reporting trends and signal detection in Japan. Pharmacoepidemiology and drug safety 2021. link 40 Salman O, Topf K, Chandler R, Conklin L. Progress in Immunization Safety Monitoring - Worldwide, 2010-2019. MMWR. Morbidity and mortality weekly report 2021. link 41 Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases. BMC public health 2021. link 42 Anderson P, Bryson J. Confronting vaccine hesitancy: What nurses need to know. Nursing 2020. link 43 Goldstein ND, Purtle J, Suder JS. Association of Vaccine-Preventable Disease Incidence With Proposed State Vaccine Exemption Legislation. JAMA pediatrics 2020. link 44 Desmond A, Offit PA. The antivax movement and what allergists can do. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2020. link 45 MacDonald NE, Guichard S, Arora N, Menning L, Wilhelm E. Lessons on causality assessment and communications from the 2019 South-East Asia Regional (SEAR) workshop on inter-country expert review of selected Adverse Events Following Immunization (AEFI) cases. Vaccine 2020. link 46 Dreisinger N, Lim CA. Resurgence of Vaccine-Preventable Disease: Ethics in the Pediatric Emergency Department. Pediatric emergency care 2019. link 47 Haq Z, Shaikh BT, Tran N, Hafeez A, Ghaffar A. System within systems: challenges and opportunities for the Expanded Programme on Immunisation in Pakistan. Health research policy and systems 2019. link 48 Soldatou V, Soldatos A, Soldatos T. Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance. BioMed research international 2019. link 49 Hotez PJ, Wolf JE. Vaccines Hesitancy and the Dermatologist. Skinmed 2018. link 50 Chang AY, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D et al.. The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. Health affairs (Project Hope) 2018. link 51 Cataldi JR, Dempsey AF, Allison MA, O'Leary ST. Impact of publicly available vaccination rates on parental school and child care choice. Vaccine 2018. link 52 Rochman-Fowler J, Duarte Walsh V, Barratt J. Adult immunisation: A key element of public health programs: Synopsis of Asia Pacific Adult Immunisation Meeting, Tokyo, 1-2 December 2016. Australasian journal on ageing 2018. link 53 Foster M, Pandey A, Kreimeyer K, Botsis T. Generation of an annotated reference standard for vaccine adverse event reports. Vaccine 2018. link 54 Singh AK, Wagner AL, Joshi J, Carlson BF, Aneja S, Boulton ML. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience. Expert review of vaccines 2018. link 55 Wang J, Zhao L, Ye Y, Zhang Y. Adverse event detection by integrating twitter data and VAERS. Journal of biomedical semantics 2018. link 56 Whitaker HJ, Ghebremichael-Weldeselassie Y, Douglas IJ, Smeeth L, Farrington CP. Investigating the assumptions of the self-controlled case series method. Statistics in medicine 2018. link 57 . Announcement: Implementation of the Vaccine Adverse Event Reporting System 2.0 Reporting Form. MMWR. Morbidity and mortality weekly report 2017. link 58 Zvanaka S, Tsitsi J, Chonzi P, Shambira G, Gombe NT, Tshimanga M. Evaluation of the adverse events following immunizations surveillance system in Harare City, Zimbabwe, 2016: a descriptive cross sectional study. The Pan African medical journal 2017. link 59 Cohet C, Rosillon D, Willame C, Haguinet F, Marenne MN, Fontaine S et al.. Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view. Vaccine 2017. link 60 Suragh TA, Miller ER, Hibbs BF, Winiecki SK, Zinderman C, Shimabukuro TT. Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form. Vaccine 2017. link 61 Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine Adverse Events: Separating Myth from Reality. American family physician 2017. link 62 Leite A, Thomas SL, Andrews NJ. Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD). Vaccine 2017. link 63 Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES et al.. Vaccine adverse events in a safety net healthcare system and a managed care organization. Vaccine 2017. link 64 . Why The Decade Of Vaccines?. Health affairs (Project Hope) 2016. link 65 Levine DA. Vaccine-Preventable Diseases In Pediatric Patients: A Review Of Measles, Mumps, Rubella, And Varicella. Pediatric emergency medicine practice 2016. link 66 Close RM, Pearson C, Cohn J. Vaccine-preventable disease and the under-utilization of immunizations in complex humanitarian emergencies. Vaccine 2016. link 67 . Committee Opinion No. 661: Integrating Immunizations Into Practice. Obstetrics and gynecology 2016. link 68 Porteous GH, Hanson NA, Sueda LA, Hoaglan CD, Dahl AB, Ohlson BB et al.. Resurgence of Vaccine-Preventable Diseases in the United States: Anesthetic and Critical Care Implications. Anesthesia and analgesia 2016. link 69 Edwards KM, Hackell JM. Countering Vaccine Hesitancy. Pediatrics 2016. link 70 Scherer LD, Shaffer VA, Patel N, Zikmund-Fisher BJ. Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust?. Vaccine 2016. link 71 Leite A, Andrews NJ, Thomas SL. Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods. Pharmacoepidemiology and drug safety 2016. link 72 Swamy GK, Heine RP. Vaccinations for pregnant women. Obstetrics and gynecology 2015. link 73 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective. American journal of preventive medicine 2015. link 74 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing vaccine safety capacity globally: A lifecycle perspective. Vaccine 2015. link 75 Wei L, Scott J. Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and drug safety 2015. link 76 Bouder F. Risk communication of vaccines: challenges in the post-trust environment. Current drug safety 2015. link 77 . In the mood for wiping out vaccine-preventable diseases. Bulletin of the World Health Organization 2014. link 78 Maro JC, Brown JS, Dal Pan GJ, Kulldorff M. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. Pharmacoepidemiology and drug safety 2014. link 79 Van Holle L, Bauchau V. The upper bound to the Relative Reporting Ratio-a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection. Pharmacoepidemiology and drug safety 2014. link 80 Scott J, Botsis T, Ball R. Simulating adverse event spontaneous reporting systems as preferential attachment networks: application to the Vaccine Adverse Event Reporting System. Applied clinical informatics 2014. link 81 Van Holle L, Bauchau V. Use of logistic regression to combine two causality criteria for signal detection in vaccine spontaneous report data. Drug safety 2014. link 82 van Holle L, Bauchau V. Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm. Pharmacoepidemiology and drug safety 2014. link 83 Xu S, Hambidge SJ, McClure DL, Daley MF, Glanz JM. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design. Statistics in medicine 2013. link 84 Das PK. Study of adverse events following immunisation with universal and newer vaccines in the Serampore IMA Child Clinic over a period of 7 years. Journal of the Indian Medical Association 2013. link 85 Van Holle L, Bauchau V. Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. Pharmacoepidemiology and drug safety 2013. link 86 Davis RL. The vaccine adverse event reporting system and vaccine safety research in the genomics era. Vaccine 2012. link 87 Wilson K, Hawken S, Kwong JC, Deeks SL, Crowcroft NS, Manuel D. Vaccine and Immunization Surveillance in Ontario (VISION) - using linked health administrative databases to monitor vaccine safety. Vaccine 2012. link 88 Black S, Egan W, Lambert PH. Post-licensure evaluation of vaccine safety: current status and future directions. Symposium organised by the International Alliance for Biological Standardization (IABS) in Barcelona, Spain, 27-28 April 2011. Biologicals : journal of the International Association of Biological Standardization 2012. link 89 Botsis T, Buttolph T, Nguyen MD, Winiecki S, Woo EJ, Ball R. Vaccine adverse event text mining system for extracting features from vaccine safety reports. Journal of the American Medical Informatics Association : JAMIA 2012. link 90 DeLong G. Conflicts of interest in vaccine safety research. Accountability in research 2012. link 91 Graham JE, Borda-Rodriguez A, Huzair F, Zinck E. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Vaccine 2012. link 92 Berry JG, Gold MS, Ryan P, Duszynski KM, Braunack-Mayer AJ. Public perspectives on consent for the linkage of data to evaluate vaccine safety. Vaccine 2012. link 93 Hussain H, Omer SB, Manganello JA, Kromm EE, Carter TC, Kan L et al.. Immunization safety in US print media, 1995-2005. Pediatrics 2011. link 94 Haber P, Iskander J, Walton K, Campbell SR, Kohl KS. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics 2011. link 95 Yih WK, Kulldorff M, Fireman BH, Shui IM, Lewis EM, Klein NP et al.. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics 2011. link 96 Kanesa-thasan N, Shaw A, Stoddard JJ, Vernon TM. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies. Pediatrics 2011. link 97 Miller E, Batten B, Hampton L, Campbell SR, Gao J, Iskander J. Tracking vaccine-safety inquiries to detect signals and monitor public concerns. Pediatrics 2011. link 98 Ball R, Botsis T. Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS?. Clinical pharmacology and therapeutics 2011. link 99 LaRussa PS, Edwards KM, Dekker CL, Klein NP, Halsey NA, Marchant C et al.. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics 2011. link 100 Leask J, Booy R, McIntyre PB. MMR, Wakefield and The Lancet: what can we learn?. The Medical journal of Australia 2010. link